Adhering to the principles of evidence-based medicine, Venus Medtech has consistently conducted long-term follow-up studies ...

LuX-Valve TTVR was performed via the transatrial approach, resulting in a procedural success rate of 97.6%, with one patient ...

Inc. (Stock Code: 2500.HK, hereinafter referred to as 'Venus Medtech' or the 'Company'), a global leader in structural heart therapies, has announced financial results for the year ended December 31, ...

Mitral/Tricuspid Valve Cardiovalve's trial in the treatment of tricuspid regurgitation enrolled nearly 120 patients across 30+ renowned cardiovascular centers in Germany, Italy, Spain, the UK ...

Key findings reported in the year include: Cardiovalve ... % severe or worse tricuspid regurgitation showed 90% reduced to ≤mild regurgitation at 30-day follow-up. VenusP-Valve (5-year CE ...

Mitral/Tricuspid Valve Cardiovalve's trial in the treatment of tricuspid regurgitation enrolled nearly 120 patients across 30+ renowned cardiovascular centers in Germany, Italy, Spain, the UK ...